GlassScriptPhysician profile
Robyn A Levy
NPI 1619162898
$4,060.37
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,189 · 2022: $1,454 · 2023: $1,418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,418.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,194.90 | 2021-2023 | |
| Lilly USA, LLC | $375.49 | 2021-2023 | Mounjaro, Trulicity, Jardiance |
| Novo Nordisk INC | $326.48 | 2021-2023 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $301.70 | 2021-2023 | Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $298.36 | 2021-2023 | Rexulti |
| Glaxosmithkline, LLC. | $252.14 | 2021-2023 | Trelegy Ellipta, Shingrix |
| Amgen INC. | $156.87 | 2021-2023 | Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $99.04 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $80.18 | 2021-2023 | |
| Abbott Laboratories | $78.27 | 2021-2023 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.67 | 2021-2022 | |
| Optinose US, INC. | $67.40 | 2021 | |
| Merck Sharp & Dohme LLC | $64.25 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $56.23 | 2021-2023 | |
| Almatica Pharma LLC | $50.68 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $50.10 | 2023 | Korlym |
| Axsome Therapeutics, INC. | $44.81 | 2022-2023 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.96 | 2022 | |
| Astellas Pharma US INC | $40.61 | 2022 | |
| Mylan Specialty L.P. | $40.36 | 2023 | Yupelri |
| Esperion Therapeutics, INC. | $39.95 | 2021 | |
| Amarin Pharma, INC. | $39.75 | 2021 | |
| Eisai INC. | $38.09 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $36.26 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.76 | 2022 | |
| Cranial Technologies, INC | $34.55 | 2022 | |
| Exact Sciences Corporation | $29.25 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $26.86 | 2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $24.18 | 2021 | |
| Alkermes, INC. | $21.05 | 2023 | Aristada, Lybalvi |
| Medtronic, INC. | $16.85 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.16 | 2022 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robyn Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.